# US 11,680,085 B2 · Cyclic peptides for protection against respiratory syncytial virus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,680,085 B2
- Document ID: US11680085B2
- Status: Granted
- Kind: B2
- Application number: 16/622,023
- Filed: 2018-06-13
- Published: 2021-04-08
- Granted: 2023-06-20
- Earliest claimed: 2017-06-14
- Assignees: Virometix AG; UniversitäT ZüRich
- Applicants: Virometix AG; UniversitäT ZüRich
- Inventors: Arin Ghasparian; Armando Zuniga; Aniebrys Marrero Nodarse; Oliver Rassek; John A. Robinson; Kerstin Möhle
- Web page: https://patentgrep.com/patent/US11680085B2

## CPC

- A61P 31/14: for RNA viruses
- C07K 14/08: RNA viruses
- A61K 39/12: Viral antigens
- A61K 47/542: {Carboxylic acids, e.g. a fatty acid or an amino acid}
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61K 47/646: {the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines}
- C07K 14/005: from viruses
- C07K 16/11: Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/5258: {Virus-like particles}
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/6018: {Lipids, e.g. in lipopeptides}
- A61K 2039/627: {characterised by the linker}
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C12N 2760/00023: Virus like particles [VLP]
- C12N 2760/18522: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/18534: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to a cyclic peptide, a conjugate comprising said cyclic peptide and a lipopeptide building block, a bundle of said conjugates, a synthetic virus-like particle comprising at least one bundle of conjugates and pharmaceutical compositions comprising the same. The present invention further relates to said cyclic peptide, said conjugate said bundle of conjugates, said synthetic virus-like particle and said pharmaceutical compositions for use as a medicament, preferably for use in a method for preventing of an infectious disease or reducing the risk of an infectious disease, more preferably for use in a method for preventing or reducing the risk of an infectious disease associated with or caused by a respiratory syncytial virus.

## Claims

### Claim 1

A cyclic peptide comprising an amino acid sequence (I), wherein said amino acid sequence (I) comprises the amino acid sequence:
X1-X2-X3-C4-X5-X6-X7-C8-X9-X10-X11-P12-I13-T14-N15-D16-Q17-K18-K19-L20-C21-X22-X23-X24-C25-X26-X27-X28-X29-X30 (SEQ ID NO: 1),
wherein X1, X2, X3, X5, X6, X7, X9, X10, X11, X22, X23, X24, X26, X27, X28 and X29 are independently of each other an amino acid;
C4, C8, C21 and C25 are independently of each other cysteine;
P12 is proline;
I13 is isoleucine;
T14 is threonine;
N15 is asparagine;
D16 is aspartic acid;
Q17 is glutamine;
K18 and K19 are independently of each other lysine;
L20 is leucine; and
X30 is an amino acid or a deletion,
wherein said cysteines C4 and C25 form a first disulfide bond and said cysteines C8 and C21 form a second disulfide bond.

### Claim 2 (depends on 1)

The cyclic peptide of claim 1, wherein said cyclic peptide has a length of at most 80 amino acids.

### Claim 3 (depends on 1)

The cyclic peptide of claim 1, wherein X11 is selected from norleucine, 6-hydroxy-norleucine, norvaline, 5-oxo-norleucine, 2-aminoheptanoic acid, methionine, ethionine, hydroxy-methionine, s-oxymethionine, methionine sulfone, or methionine sulfoxide.

### Claim 4 (depends on 1)

The cyclic peptide of claim 1, wherein X23 is selected from asparagine, beta-hydroxyasparagine, 2,5-diamino-4-hydroxy-5-oxopentanoic acid, glutamine, glutamine hydroxamate, 3-methyl-glutamine, n-methyl-asparagine, n5-methyl-glutamine, cysteine-s-acetamide; serine, homoserine, allo-threonine, 3,3-dihydroxy-alanine, 2-amino-5-hydroxypentanoic acid, 4-hydroxy-l-threonine, threonine, hydroxynorvaline, 6-hydroxy-l-norleucine or glycine.

### Claim 5 (depends on 1)

The cyclic peptide of claim 1, wherein X24 is selected from asparagine, beta-hydroxyasparagine, 2,5-diamino-4-hydroxy-5-oxopentanoic acid, glutamine, glutamine hydroxamate, 3-methyl-glutamine, n-methyl-asparagine, n5-methyl-glutamine, cysteine-s-acetamide; lysine, 2,4-diaminobutyric acid, 2,3-diaminopropanoic acid, 2,8-diaminooctanoic acid, ornithine, amino-adipic acid, thialysine; aspartic acid, 2-amino-6-oxopimelic acid, 3-methyl-aspartic acid, l-2-amino-6-methylene-pimelic acid, 4-hydroxy-glutamic-acid, 6-carboxylysine, beta-hydroxyaspartic acid, 3,3-dimethyl aspartic acid, 2-amino-propanedioic acid, glutamate, 5-o-methyl-glutamic acid, (3r)-3-methyl-l-glutamic acid, (3s)-3-methyl-l-glutamic acid, 2s,4r-4-methylglutamate 2-aminoadipic acid, serine, homoserine, allo-threonine, 3,3-dihydroxy-alanine, 2-amino-5-hydroxypentanoic acid, 4-hydroxy-l-threonine, threonine, hydroxynorvaline, 6-hydroxy-l-norleucine or glycine.

### Claim 6 (depends on 1)

The cyclic peptide of claim 1, wherein the C-terminal amino acid of said amino acid sequence (I) is selected from alanine, leucine, valine, norleucine, norvaline, isoleucine, homoleucine, vinylglycine, 2-aminobutyric acid, 2-allylglycine, alloleucine, alloisoleucine, 2-aminoheptanoic acid, serine, glutamine or glycine.

### Claim 7 (depends on 1)

The cyclic peptide of claim 1, wherein the amino acid sequence (I) is an amino acid sequence selected from any one of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO:5, SEQ ID NO: 16 to SEQ ID NO: 36 or SEQ ID NO: 39 to 57.

### Claim 8 (depends on 1)

The cyclic peptide of claim 1 further comprising a linker, wherein said linker is attached to said amino acid sequence (I), and wherein said linker comprises (i) at least one attachment moiety, (ii) at least one spacer moiety, (iii) at least one linking moiety, or (iv) any combination of (i), (ii) and (iii).

### Claim 9 (depends on 8)

The cyclic peptide of claim 8, wherein said linker is selected from the following formulas:
wherein n is an integer of 1 to 45, and the wavy line indicates the attachment site to said amino acid sequence (I).

### Claim 10 (depends on 1)

A conjugate comprising
(a) a lipopeptide building block, and
(b) the cyclic peptide of claim 1,
wherein said lipopeptide building block consists of
(i) a peptide moiety comprising at least one coiled coil peptide chain segment, and
(ii) a lipid moiety comprising two or three hydrocarbyl chains;
and wherein said cyclic peptide is connected, directly or via a linker, to said lipopeptide building block.

### Claim 11 (depends on 10)

The conjugate of claim 10, wherein said conjugate is selected from any one of the formulas

### Claim 12 (depends on 10)

A bundle of conjugates comprising 2, 3, 4, 5, 6 or 7 conjugates of claim 10.

### Claim 13 (depends on 11)

A synthetic virus-like particle comprising at least one bundle of conjugates of claim 11.

### Claim 14 (depends on 13)

A pharmaceutical composition comprising an immunologically effective amount of the synthetic virus like particle of claim 13, together with a pharmaceutically acceptable diluent, carrier or excipient.

### Claim 15 (depends on 1)

The cyclic peptide of claim 1, wherein said cyclic peptide has a length of at most 40 amino acids.

### Claim 16 (depends on 8)

The cyclic peptide of claim 8 wherein said at least one attachment moiety comprises —O—NH2, —O—NH—, —C(O)—CH2—O—NH2, —C(O)—CH2—O—NH—, —N—NH2, —N—NH—, -E(O)—NH—NH2, or -E(O)—NH—NH—, wherein E is C, S(O) or P.

### Claim 17 (depends on 10)

The conjugate of claim 10, wherein said lipid moiety comprises two hydrocarbyl chains.

### Claim 18 (depends on 10)

The conjugate of claim 10, wherein said conjugate is of formula 12.

### Claim 19 (depends on 16)

The cyclic peptide of claim 16, wherein said at least one spacer moiety comprises NH2—CH2—CH2—(O—CH2—CH2)n—C(O)— or —NH—CH2—CH2—(O—CH2—CH2)n—C(O)—, wherein n is an integer of 2 to 20; or NH2—(CH2)m—C(O)— or —NH—(CH2)m—C(O)—, wherein m is an integer of 2 to 20; and wherein said at least one linking moiety is capable of cross-linking the cyclic peptide with a second peptide.

### Claim 20 (depends on 16)

The cyclic peptide of claim 16, wherein said at least one spacer moiety comprises NH2—CH2—CH2—(O—CH2—CH2)n—C(O)— or —NH—CH2—CH2—(O—CH2—CH2), —C(O)—, wherein n is an integer of 6 to 8; or NH2—(CH2)m—C(O)— or —NH—(CH2)m—C(O)—, wherein m is an integer of 2 to 6; and wherein said at least one linking moiety is capable of cross-linking the cyclic peptide with a second peptide.
